A review of recent litigation from Sara Koblitz, a director at Hyman, Phelps & McNamara, provides reason to think that so-called skinny-labeled drugs will conti 12 January 2022
The US District Court for the District of Delaware has held that Eagle Pharmaceuticals’ proposed vasopressin product does not infringe any of the patents that P 1 September 2021
The US Food and Drug Administration (FDA) has published a revision to its Manual of Policies and Procedures (MAPP), Generic Drug Labeling Revisions Under Sectio 27 July 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.